AYTU - Aytu BioScience, Inc.
| Previous Close | 0.8200 |
| Open | 0.8400 |
| Bid | 0.8449 x 1100 |
| Ask | 0.8500 x 800 |
| Day's Range | 0.8023 - 0.8424 |
| 52 Week Range | 0.6500 - 2.6100 |
| Volume | 60,058 |
| Avg. Volume | 136,652 |
| Market Cap | 16.684M |
| Beta (5Y Monthly) | 3.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5910 |
| Earnings Date | Feb 04, 2020 - Feb 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.88 |
- ACCESSWIRE
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
ENGLEWOOD, CO and SAN DIEGO, CA / ACCESSWIRE / December 24, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 containing a joint preliminary proxy statement/prospectus in connection with Aytu BioScience's proposed acquisition of Innovus Pharmaceuticals on December 23, 2019 after markets closed. The registration statement containing the joint preliminary proxy statement/prospectus is available through the SEC's website at www.sec.gov and on each company's website on the respective company's Investor section.
- Insider Monkey
Hedge Funds Are Warming Up To Aytu BioScience, Inc. (AYTU)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- GlobeNewswire
Rigrodsky & Long, P.A. Files Class Action Suit Against Aytu BioScience, Inc.
WILMINGTON, Del., Dec. 17, 2019 -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District.
- ACCESSWIRE
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Following Transaction
NEW YORK, NY / ACCESSWIRE / December 14, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
- Zacks Small Cap Research
CERC: Expansion in Rare and Orphan Diseases with Acquisition of Aevi Genomic Medicine…
By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update Acquisition of Aevi Genomic Medicine Strengthens Rare and Orphan Disease Pipeline On December 5, 2019, Cerecor, Inc. (NASDAQ:CERC) announced the acquisition of Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million plus contingent value rights (CVRs) for up to an additional
- GlobeNewswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers
WILMINGTON, Del., Dec. 12, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible.
- PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 21, 2019 Preliminary Proxy Statement of AYTU BIOSCIENCE, INC. - AYTU
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aytu BioScience, Inc. ("Aytu BioScience" or the "Company")(Nasdaq: AYTU) and its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the Purchase Agreement with Cerecor Inc for its pediatric and primary care product lines (the "Purchase Agreement").
- Thomson Reuters StreetEvents
Edited Transcript of AYTU earnings conference call or presentation 14-Nov-19 9:30pm GMT
Q1 2020 Aytu BioScience Inc Earnings Call
- ACCESSWIRE
MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine
ENGLEWOOD, CO / ACCESSWIRE / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, ...
- ACCESSWIRE
Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019
ENGLEWOOD, CO / ACCESSWIRE / December 3, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical ...
- ACCESSWIRE
Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals
Expanded Commercial Operations Expected to Accelerate Natesto Growth in the U.S. ENGLEWOOD, CO / ACCESSWIRE / December 2, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the launch of the company's co-promotion with Acerus Pharmaceuticals ("Acerus") which is expected to accelerate the growth of in the United States. Through this expanded commercial relationship, Acerus has launched a U.S.-based specialty sales force promoting Natesto to urologists and endocrinologists.
- ACCESSWIRE
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager’s National Formulary
ENGLEWOOD, CO / ACCESSWIRE / November 19, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Tuzistra® XR, the only FDA-approved 12-hour codeine-based cold-cough syrup, is now covered by a leading national pharmacy benefit manager (PBM). This PBM contract provides more than six million covered lives with unrestricted patient access to Tuzistra XR across the PBM's national formularies and client plans servicing government clients.
- Zacks
Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates
Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
Aytu Reports First Quarter 2020 Financial Results
ENGLEWOOD, CO / ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical ...
- ACCESSWIRE
Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations
ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's Executive Vice President of Commercial Operations. Mr. Phillips' hiring became effective November 8, 2019 following the recently announced acquisition of a portfolio of six prescription products from Cerecor, Inc. (the "Commercial Portfolio") and the accompanying commercial team supporting the products' growth.
- ACCESSWIRE
Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter ended September 30, 2019 on November 14, 2019, at 4:30 p.m. ET. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.
- GlobeNewswire
Kaskela Law LLC Announces Stockholder Investigation of Aytu BioScience, Inc. – AYTU
PHILADELPHIA, Nov. 04, 2019 -- Kaskela Law LLC is investigating Aytu BioScience, Inc. (“Aytu”) (NASDAQ: AYTU) on behalf of the company’s stockholders. The investigation seeks.
- ACCESSWIRE
Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase
ENGLEWOOD, CO / ACCESSWIRE / November 4, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of the previously announced purchase of a $12.4M annual revenue prescription product portfolio (the "Commercial Portfolio") and accompanying commercial infrastructure from Cerecor. With this acquisition, along with the previously announced acquisition of Innovus Pharmaceuticals, combined company annual revenue increases to over $44 million, based on combined company revenue for the twelve months ending June 30, 2019.
- American City Business Journals
Form D Friday: Greenwood Village-based securities firm raising $50M for real estate fund
Form D Friday is a Denver Business Journal feature highlighting regulatory filings from Denver-area companies raising capital for new projects, creating new venture funds or expanding their businesses. Parsonex Opportunity Fund I of Englewood is raising $50 million in common units of LLC membership interests for a business in the real estate industry, according to a Form D filed on Oct. 29. There is one investor so far.
- ACCESSWIRE
Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary
Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions ...
- ACCESSWIRE
Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone ...
- ACCESSWIRE
Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
Investigator-initiated, Phase IV study results will be presented today at 75 th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session ENGLEWOOD, ...
- ACCESSWIRE
Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced the signing of an asset purchase agreement to acquire a portfolio of prescription products from Cerecor, Inc. (the "Commercial Portfolio"). The Commercial Portfolio and accompanying commercial infrastructure generated $12.4 million in net revenue and was profitable on a standalone basis for the twelve months ending June 30, 2019.
- ACCESSWIRE
Aytu BioScience Announces $10 Million Private Placement
ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is pleased to announce that it has entered into definitive agreements with two institutional investors for the purchase and sale in a private placement of $10 Million of Series F Convertible Preferred Stock and warrants to purchase common stock. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing.
- ACCESSWIRE
Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market
Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions ...
